Performance of a stool-based quantitative PCR assay for the diagnosis of tuberculosis in adolescents and adults: a multinational, prospective diagnostic accuracy study.


Journal

The Lancet. Microbe
ISSN: 2666-5247
Titre abrégé: Lancet Microbe
Pays: England
ID NLM: 101769019

Informations de publication

Date de publication:
07 Mar 2024
Historique:
received: 23 06 2023
revised: 23 10 2023
accepted: 21 11 2023
medline: 11 3 2024
pubmed: 11 3 2024
entrez: 10 3 2024
Statut: aheadofprint

Résumé

Despite increasing availability of rapid molecular tests for the diagnosis of tuberculosis in high-burden settings, many people with tuberculosis are undiagnosed. Reliance on sputum as the primary specimen for tuberculosis diagnostics contributes to this diagnostic gap. We evaluated the diagnostic accuracy and additive yield of a novel stool quantitative PCR (qPCR) assay for the diagnosis of tuberculosis in three countries in Africa with high tuberculosis burdens. We undertook a prospective diagnostic accuracy study in Eswatini, Mozambique, and Tanzania from Sept 21, 2020, to Feb 2, 2023, to compare the diagnostic accuracy for tuberculosis of a novel stool qPCR test with the current diagnostic standard for Mycobacterium tuberculosis DNA detection from sputum and stool, Xpert-MTB/RIF Ultra (Xpert Ultra). Sputum, stool, and urine samples were provided by a cohort of participants, aged 10 years or older, diagnosed with tuberculosis. Participants with tuberculosis (cases) were enrolled within 72 h of treatment initiation for tuberculosis diagnosed clinically or following laboratory confirmation. Participants without tuberculosis (controls) consisted of household contacts of the cases who did not develop tuberculosis during a 6-month follow-up. The performance was compared with a robust composite microbiological reference standard (CMRS). The cohort of adolescents and adults (n=408) included 268 participants with confirmed or clinical tuberculosis (cases), 147 (55%) of whom were living with HIV, and 140 participants (controls) without tuberculosis. The sensitivity of the novel stool qPCR was 93·7% (95% CI 87·4-97·4) compared with participants with detectable growth on M tuberculosis culture, and 88·1% (81·3-93·0) compared with sputum Xpert Ultra. The stool qPCR had an equivalent sensitivity as sputum Xpert Ultra (94·8%, 89·1-98·1) compared with culture. Compared with the CMRS, the sensitivity of the stool qPCR was higher than the current standard for tuberculosis diagnostics on stool, Xpert Ultra (80·4%, 73·4-86·2 vs 73·5%, 66·0-80·1; p=0·025 on paired comparison). The qPCR also identified 17-21% additional tuberculosis cases compared to sputum Xpert Ultra or sputum culture. In controls without tuberculosis, the specificity of the stool qPCR was 96·9% (92·2-99·1). In this study, a novel qPCR for the diagnosis of tuberculosis from stool specimens had a higher accuracy in adolescents and adults than the current diagnostic PCR gold standard on stool, Xpert-MTB/RIF Ultra, and equivalent sensitivity to Xpert-MTB/RIF Ultra on sputum. National Institutes of Health (NIH) Allergy and Infectious Diseases, and NIH Fogarty International Center.

Sections du résumé

BACKGROUND BACKGROUND
Despite increasing availability of rapid molecular tests for the diagnosis of tuberculosis in high-burden settings, many people with tuberculosis are undiagnosed. Reliance on sputum as the primary specimen for tuberculosis diagnostics contributes to this diagnostic gap. We evaluated the diagnostic accuracy and additive yield of a novel stool quantitative PCR (qPCR) assay for the diagnosis of tuberculosis in three countries in Africa with high tuberculosis burdens.
METHODS METHODS
We undertook a prospective diagnostic accuracy study in Eswatini, Mozambique, and Tanzania from Sept 21, 2020, to Feb 2, 2023, to compare the diagnostic accuracy for tuberculosis of a novel stool qPCR test with the current diagnostic standard for Mycobacterium tuberculosis DNA detection from sputum and stool, Xpert-MTB/RIF Ultra (Xpert Ultra). Sputum, stool, and urine samples were provided by a cohort of participants, aged 10 years or older, diagnosed with tuberculosis. Participants with tuberculosis (cases) were enrolled within 72 h of treatment initiation for tuberculosis diagnosed clinically or following laboratory confirmation. Participants without tuberculosis (controls) consisted of household contacts of the cases who did not develop tuberculosis during a 6-month follow-up. The performance was compared with a robust composite microbiological reference standard (CMRS).
FINDINGS RESULTS
The cohort of adolescents and adults (n=408) included 268 participants with confirmed or clinical tuberculosis (cases), 147 (55%) of whom were living with HIV, and 140 participants (controls) without tuberculosis. The sensitivity of the novel stool qPCR was 93·7% (95% CI 87·4-97·4) compared with participants with detectable growth on M tuberculosis culture, and 88·1% (81·3-93·0) compared with sputum Xpert Ultra. The stool qPCR had an equivalent sensitivity as sputum Xpert Ultra (94·8%, 89·1-98·1) compared with culture. Compared with the CMRS, the sensitivity of the stool qPCR was higher than the current standard for tuberculosis diagnostics on stool, Xpert Ultra (80·4%, 73·4-86·2 vs 73·5%, 66·0-80·1; p=0·025 on paired comparison). The qPCR also identified 17-21% additional tuberculosis cases compared to sputum Xpert Ultra or sputum culture. In controls without tuberculosis, the specificity of the stool qPCR was 96·9% (92·2-99·1).
INTERPRETATION CONCLUSIONS
In this study, a novel qPCR for the diagnosis of tuberculosis from stool specimens had a higher accuracy in adolescents and adults than the current diagnostic PCR gold standard on stool, Xpert-MTB/RIF Ultra, and equivalent sensitivity to Xpert-MTB/RIF Ultra on sputum.
FUNDING BACKGROUND
National Institutes of Health (NIH) Allergy and Infectious Diseases, and NIH Fogarty International Center.

Identifiants

pubmed: 38461830
pii: S2666-5247(23)00391-9
doi: 10.1016/S2666-5247(23)00391-9
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests CL has received funding for this work from the German Center for Infection Research (DZIF); consulting fees from Insmed; and speakers' honoraria from Insmed, Gilead, GSK, and Janssen outside of the scope of this work. AMM has received honoraria from Janssen for participation in a data and safety monitoring board outside of the scope of this work. All other authors declare no competing interests.

Auteurs

Alexander Kay (A)

Global TB Program, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; Baylor College of Medicine Children's Foundation Eswatini, Mbabane, Eswatini. Electronic address: Alexander.Kay@bcm.edu.

Anca Vasiliu (A)

Global TB Program, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.

Lucia Carratala-Castro (L)

Barcelona Institute for Global Health, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; Centro de Investigação em Saude de Manhiça (CISM), Maputo, Mozambique.

Bariki Mtafya (B)

National Institute for Medical Research (NIMR)-Mbeya Medical Research Center, Mbeya, Tanzania.

Jose Euberto Mendez Reyes (JE)

Global TB Program, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.

Nontobeko Maphalala (N)

Baylor College of Medicine Children's Foundation Eswatini, Mbabane, Eswatini.

Shilzia Munguambe (S)

Centro de Investigação em Saude de Manhiça (CISM), Maputo, Mozambique.

Durbbin Mulengwa (D)

Baylor College of Medicine Children's Foundation Eswatini, Mbabane, Eswatini.

Tara Ness (T)

Global TB Program, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.

Belen Saavedra (B)

Barcelona Institute for Global Health, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; Centro de Investigação em Saude de Manhiça (CISM), Maputo, Mozambique.

Jason Bacha (J)

Baylor College of Medicine Children's Foundation Mbeya, Mbeya, Tanzania.

Gugu Maphalala (G)

Eswatini Health Laboratory Service, Mbabane, Eswatini.

Rojelio Mejia (R)

Pediatric Tropical Medicine, Baylor College of Medicine, Houston, TX, USA.

Godwin Mtetwa (G)

Global TB Program, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.

Sozinho Acacio (S)

Centro de Investigação em Saude de Manhiça (CISM), Maputo, Mozambique.

Patricia Manjate (P)

Centro de Investigação em Saude de Manhiça (CISM), Maputo, Mozambique.

Edson Mambuque (E)

Centro de Investigação em Saude de Manhiça (CISM), Maputo, Mozambique.

Nosisa Shiba (N)

Baylor College of Medicine Children's Foundation Eswatini, Mbabane, Eswatini.

Nokwanda Kota (N)

Baylor College of Medicine Children's Foundation Eswatini, Mbabane, Eswatini.

Mangaliso Ziyane (M)

Baylor College of Medicine Children's Foundation Eswatini, Mbabane, Eswatini; Eswatini Health Laboratory Service, Mbabane, Eswatini.

Nyanda Elias Ntinginya (NE)

National Institute for Medical Research (NIMR)-Mbeya Medical Research Center, Mbeya, Tanzania.

Christoph Lange (C)

Global TB Program, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany; Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany.

H Lester Kirchner (HL)

Global TB Program, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; Department of Population Health Sciences, Geisinger, Danville, PA, USA.

Andrew R DiNardo (AR)

Global TB Program, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.

Alberto L Garcia-Basteiro (AL)

Barcelona Institute for Global Health, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; Centro de Investigação em Saude de Manhiça (CISM), Maputo, Mozambique; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Barcelona, Spain.

Anna Maria Mandalakas (AM)

Global TB Program, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany; Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany; Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas Health School of Public Health, Houston, TX, USA.

Classifications MeSH